Amy B. Heimberger
#124,875
Most Influential Person Now
American neurosurgeon and physician-scientist
Amy B. Heimberger's AcademicInfluence.com Rankings
Amy B. Heimbergerphilosophy Degrees
Philosophy
#8366
World Rank
#11729
Historical Rank
#1694
USA Rank
Logic
#5398
World Rank
#6792
Historical Rank
#886
USA Rank
Amy B. Heimbergerbiology Degrees
Biology
#10133
World Rank
#13432
Historical Rank
#2480
USA Rank
Immunology
#726
World Rank
#748
Historical Rank
#96
USA Rank
Download Badge
Philosophy Biology
Amy B. Heimberger's Degrees
- Doctorate Medicine University of Texas Medical Branch
Why Is Amy B. Heimberger Influential?
(Suggest an Edit or Addition)According to Wikipedia, Amy B. Heimberger is an American neurosurgeon and physician-scientist. She is the Jean Malnati Miller Professor of Neurological Surgery, vice-chair for research in the department of neurological Surgery at Feinberg School of Medicine and scientific director of The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center.
Amy B. Heimberger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. (1990) (2104)
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. (2017) (1019)
- Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. (2013) (820)
- Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. (1992) (745)
- Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. (2010) (715)
- Glioma cancer stem cells induce immunosuppressive macrophages/microglia. (2010) (547)
- The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. (2006) (546)
- Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients (2005) (490)
- PD-L1 expression and prognostic impact in glioblastoma. (2016) (410)
- Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. (2017) (391)
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. (2021) (356)
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. (2011) (318)
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. (2015) (318)
- Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. (2016) (311)
- Altered adenosine-to-inosine RNA editing in human cancer. (2007) (308)
- A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. (2007) (308)
- Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. (2007) (302)
- Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. (2015) (293)
- Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas (2008) (290)
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy (2017) (287)
- Consensus on the role of human cytomegalovirus in glioblastoma. (2012) (270)
- Immunosuppressive mechanisms in glioblastoma. (2015) (249)
- Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway (2010) (248)
- An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme (2009) (248)
- Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression (2010) (230)
- miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. (2013) (226)
- Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. (2003) (226)
- Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy (2007) (226)
- AWAKE CRANIOTOMY FOR BRAIN TUMORS NEAR ELOQUENT CORTEX: CORRELATION OF INTRAOPERATIVE CORTICAL MAPPING WITH NEUROLOGICAL OUTCOMES IN 309 CONSECUTIVE PATIENTS (2009) (206)
- Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group (2012) (205)
- The natural history of EGFR and EGFRvIII in glioblastoma patients (2005) (200)
- Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes (2017) (199)
- Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma (2006) (193)
- The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas (2008) (186)
- Hypoxia Potentiates Glioma-Mediated Immunosuppression (2011) (184)
- Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). (2002) (183)
- The Controversial Role of Microglia in Malignant Gliomas (2013) (178)
- Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target (2018) (178)
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma (2019) (177)
- Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas (2013) (176)
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. (2008) (165)
- MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. (2016) (153)
- Central nervous system cancers. (2011) (145)
- EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma (2009) (132)
- Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma (2000) (129)
- Glioma-Associated Cytomegalovirus Mediates Subversion of the Monocyte Lineage to a Tumor Propagating Phenotype (2011) (124)
- A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. (2013) (122)
- Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. (2008) (117)
- Central nervous system cancers: Clinical Practice Guidelines in Oncology. (2005) (117)
- A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells (2008) (115)
- Innate immune functions of microglia isolated from human glioma patients (2006) (115)
- Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma (2002) (113)
- Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. (2014) (111)
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. (2016) (107)
- Erratum: Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment (Cancer Cell (2017) 32(1) (42–56.e6)(S1535610817302532)(10.1016/j.ccell.2017.06.003)) (2018) (105)
- Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia (2009) (104)
- Prospective Randomized Trial of Post-operative Stereotactic Radiosurgery versus Observation for Completely Resected Brain Metastases (2017) (95)
- Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? (2011) (94)
- Differential regulation of T helper phenotype development by interleukins 4 and 10 in an c43 T-cell-receptor transgenic system (93)
- Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege (2014) (92)
- Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications. (2019) (90)
- The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients (2009) (86)
- FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. (2015) (85)
- IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era (2009) (81)
- Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. (2012) (80)
- FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. (2015) (79)
- Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma (2012) (78)
- Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy (2014) (76)
- A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells (2009) (75)
- Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. (2019) (74)
- miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. (2016) (73)
- Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. (2005) (72)
- Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation (2016) (68)
- A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. (2003) (67)
- Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses (2010) (67)
- Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma (2018) (66)
- Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. (2000) (66)
- The role of tregs in glioma-mediated immunosuppression: potential target for intervention. (2010) (59)
- FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (58)
- Serum microRNA profiling in patients with glioblastoma: a survival analysis (2017) (56)
- Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma (2020) (55)
- The role of STAT3 in tumor-mediated immune suppression (2015) (55)
- Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment (2020) (54)
- Inhibition of p-STAT3 Enhances IFN-α Efficacy against Metastatic Melanoma in a Murine Model (2010) (53)
- Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas (2018) (52)
- Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment (2016) (52)
- Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. (2004) (51)
- Compartmentalization of catalases in Escherichia coli. (1988) (51)
- Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. (2008) (51)
- The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications (2014) (50)
- Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes (2016) (48)
- Targeting the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells. (2021) (47)
- Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs. Photons. (2020) (46)
- Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2 (2018) (43)
- Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy (2020) (43)
- Tumor Vaccines for Malignant Gliomas (2017) (43)
- The tumor microenvironment expression of p‐STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models (2012) (41)
- Immunotherapy for human glioma: innovative approaches and recent results (2005) (40)
- Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. (2006) (40)
- Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM (2008) (40)
- Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells (2020) (39)
- Preferential migration of regulatory T cells mediated by gliomasecreted chemokines can be blocked with chemotherapy (2007) (38)
- Comparative molecular life history of spontaneous canine and human gliomas (2019) (37)
- Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells (2016) (37)
- Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. (2020) (36)
- ATPS-68COMBINATION OF TOPOISOMERASE II POISON BERUBICIN WITH STAT3 INHIBITOR WP1066BLOCKS POTENTLY TUMOR GROWTH IN GMB MODELS (2015) (36)
- The immune landscape of common CNS malignancies: implications for immunotherapy (2021) (35)
- The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma (2021) (34)
- Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration (2020) (33)
- Mechanisms of action of rapamycin in gliomas. (2005) (33)
- MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer. (2016) (32)
- Immune therapeutic targeting of glioma cancer stem cells (2010) (32)
- Immune modulatory nanoparticle therapeutics for intracerebral glioma (2016) (31)
- Prioritization schema for immunotherapy clinical trials in glioblastoma (2016) (31)
- miR-138 exerts anti-glioma efficacy by targeting immune checkpoints (2013) (31)
- Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα-mediated lipid metabolism. (2020) (30)
- The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma (2018) (30)
- Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target (2007) (30)
- Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases. (2019) (29)
- Epidermal growth factor receptor and variant III targeted immunotherapy. (2014) (28)
- Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. (2019) (28)
- Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme (2021) (28)
- Profiles of brain metastases: Prioritization of therapeutic targets (2017) (28)
- Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models (2021) (28)
- Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. (2008) (27)
- Systematic review of combinations of targeted or immunotherapy in advanced solid tumors (2021) (27)
- Postoperative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study (2016) (27)
- Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor (2016) (27)
- The Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival (2012) (26)
- A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. (2021) (26)
- Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy (2020) (25)
- Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD) (2019) (25)
- GBM-associated mutations and altered protein expression are more common in young patients (2016) (25)
- Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors. (2020) (25)
- Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. (2018) (24)
- Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function (2019) (24)
- Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors (2020) (24)
- Primary CNS lymphoma commonly expresses immune response biomarkers (2020) (23)
- Immune Checkpoint Inhibitors in Gliomas (2017) (22)
- Identification of metabolites in plasma for predicting survival in glioblastoma (2018) (21)
- The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. (2008) (21)
- POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families (2020) (20)
- CD8+ T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas (2019) (20)
- Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes (2018) (20)
- Clinical applications of a peptide-based vaccine for glioblastoma. (2010) (20)
- Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. (2018) (20)
- Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design (2018) (19)
- Topotecan enhances immune clearance of gliomas (2009) (19)
- Immune Checkpoint Inhibitors for Brain Metastases (2017) (19)
- Circadian regulation of cancer cell and tumor microenvironment crosstalk. (2021) (19)
- Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). (2020) (18)
- Temozolomide as a vaccine adjuvant in GBM (2007) (18)
- Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial (2020) (17)
- Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer (2014) (17)
- Steering CAR T cells to distinguish friend from foe (2017) (17)
- Therapeutic targets in subependymoma (2014) (16)
- Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma (2017) (16)
- Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type (2021) (16)
- ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (2021) (16)
- The Role of Glioma Microenvironment in Immune Modulation: Potential Targets for Intervention (2006) (16)
- Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms. (2021) (14)
- Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. (2022) (13)
- Interrogating Metabolism in Brain Cancer. (2016) (13)
- The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies (2011) (13)
- Catalase HPI influences membrane permeability in Escherichia coli following near-UV stress. (1990) (13)
- FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. (2021) (13)
- BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide (2013) (13)
- What is the Burden of Proof for Tumor Mutational Burden in gliomas? (2020) (13)
- Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma (2021) (12)
- Rethinking medulloblastoma from a targeted therapeutics perspective (2018) (12)
- Radiomic analysis of pseudo-progression compared to true progression in glioblastoma patients: A large-scale multi-institutional study. (2017) (11)
- Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers (2021) (11)
- Qki is an essential regulator of microglial phagocytosis in demyelination (2020) (10)
- Tumor-derived mesenchymal stem cells in human gliomas: Isolation and biological properties (2008) (10)
- The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia (2021) (10)
- Immunotherapy in glioblastoma: emerging options in precision medicine. (2016) (10)
- Biphasic malignant meningioma: a comparative genomic hybridization study. (2002) (9)
- miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. (2011) (9)
- Chapter 19 – Prognostic Factors for Survival in Melanoma Patients with Brain Metastases (2016) (9)
- CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas (2020) (9)
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 (2020) (9)
- Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. (2022) (9)
- Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. (2016) (9)
- Biological Principles of Brain Tumor Immunotherapy (2001) (9)
- Principles of immunotherapy. (2016) (9)
- Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB‐dependent proneural glioma model by suppressing apoptosis (2015) (9)
- Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling (2021) (9)
- Erratum: Preferential migration of regulatory T cells mediated by gliomasecreted chemokines can be blocked with chemotherapy (Cancer Immunology, Immunotherapy DOI: 10.1007/s00262-007-0336-x) (2008) (8)
- yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients (2009) (8)
- Ependymomas overexpress chemoresistance and DNA repair-related proteins (2017) (8)
- RNA-Seq analysis of glioma tumors to reveal targetable gene fusions. (2017) (8)
- MiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme (2020) (8)
- MicroRNAs as novel immunotherapeutics (2013) (7)
- Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy (2021) (7)
- A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram (2020) (7)
- Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma (2021) (7)
- Targeting the Tumor Microenvironment in Brain Metastasis. (2020) (6)
- A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma (2022) (6)
- Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma (2019) (6)
- The Role of Myeloid-Derived Suppressor Cells in Immunosuppression in Brain Tumors (2017) (6)
- Reply to M.S. Lesniak (2011) (6)
- Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (6)
- Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. (2022) (6)
- Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma". (2018) (6)
- Cytochrome P450 1B1Expression in Glial CellTumors: An Immunotherapeutic Target (2007) (5)
- Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope? (2016) (5)
- Inhibition of the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells (2020) (5)
- Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression (2016) (5)
- TMIC-60. COMPREHENSIVE SPATIAL CHARACTERIZATION OF IMMUNE CELLS IN THE CNS BRAIN TUMOR MICROENVIRONMENT (2019) (4)
- Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system (2022) (4)
- ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer (2018) (4)
- IMCT-07THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD). (2015) (4)
- Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment (2019) (4)
- Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression (2022) (4)
- Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). (2021) (4)
- IMPS-28PD-L1 EXPRESSION AND PROGNOSTIC IMPACT IN GLIOBLASTOMA (2015) (3)
- NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors (2021) (3)
- New Approaches to Glioblastoma. (2021) (3)
- Artificial intelligence in the radiomic analysis of glioblastomas: A review, taxonomy, and perspective (2022) (3)
- B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model (2022) (3)
- Incidence and Prognostic Impact of FoxP3 Regulatory TCells in Human Gliomas (2008) (3)
- Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma (2020) (3)
- Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy (2023) (3)
- FoxM 1 Drives a Feed-Forward STAT 3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells (2015) (3)
- Immune landscape of a genetically engineered murine model of glioma compared with human glioma (2022) (3)
- Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients (2017) (3)
- ATIM-10. A PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS CMV-SPECIFIC CYTOTOXIC T CELLS (CMV-TC) FOR GLIOBLASTOMA: DOSE ESCALATION AND CORRELATIVE RESULTS (2018) (3)
- Glioblastoma stem cells mediate immune suppression that can be inhibited with Jak2/Stat3 blockade (2008) (3)
- IMMU-35. TRANSCRIPTIONALLY DEFINED IMMUNE CONTEXTURE IN HUMAN GLIOMAS AT SINGLE-CELL RESOLUTION (2020) (2)
- Determining venous thromboembolism risk in patients with adult-type diffuse glioma. (2022) (2)
- CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease (2021) (2)
- Innovative Treatment Strategies for High-Grade Gliomas (2007) (2)
- Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment (2021) (2)
- Validation of cancer-type dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. (2022) (2)
- Next Steps for Immunotherapy in Glioblastoma (2022) (2)
- Abstract 3251: Blockade of HIF-1 with a small molecule inhibitor WP1066 in melanoma. (2013) (2)
- POLYMORPHISMS IN MYELOID-ASSOCIATED GENES PREDICT GLIOMA SURVIVAL (2016) (2)
- RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS (2018) (2)
- CXCR4 expression is associated with proneural‐to‐mesenchymal transition in glioblastoma (2022) (2)
- Abstract 3040: Radiomics discriminates pseudo-progression from true progression in glioblastoma patients: A large-scale multi-institutional study (2018) (2)
- Reply to M.C. Chamberlain (2011) (2)
- Reply to: "Real-world prevalence across 159,872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab." by D. Fabrizio et al. (2021) (2)
- Tumor Vaccines for Malignant Gliomas (2017) (1)
- 213 Radiomic Machine Learning Algorithms Discriminate Pseudo-Progression From True Progression in Glioblastoma Patients: A Multi-Institutional Study (2018) (1)
- TMIC-09GLIOBLASTOMA STEM CELL-DERIVED EXOSOMES PROMOTE M2 POLARIZATION OF HUMAN MONOCYTES (2015) (1)
- Abstract 1492: Chimeric antigen receptor (CAR) T cell donor dependent dysfunction modulation with activation of autophagy and inhibition of trogocytosis (2021) (1)
- Abstract 4540: Development of orally bioavailable formulation of WP1066 and its evaluationin vivo (2015) (1)
- NIMG-91. RADIOMIC ANALYSIS OF PSEUDO-PROGRESSION COMPARED TO TRUE PROGRESSION IN GLIOBLASTOMA PATIENTS: A LARGE-SCALE MULTI-INSTITUTIONAL STUDY (2017) (1)
- Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment (2021) (1)
- Abstract B82: Immune signatures of glioblastoma subtypes: Extrapolation from the Cancer Genome Atlas. (2013) (1)
- Abstract 1176: Genomic profiling of canine glioma: Comparative analyses with respect to drivers of human glioma (2018) (1)
- Brain tumor-induced neuronal stress orchestrates adaptive immune surveillance through fractalkine (2018) (1)
- LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY (2012) (1)
- NIMG-03. RADIOMIC TEXTURE ANALYSIS TO PREDICT RESPONSE TO IMMUNOTHERAPY (2018) (1)
- MLTI-10. ESTABLISHMENT OF A MULTIDISCIPLINARY BRAIN METASTASIS CLINIC TO FACILITATE PATIENT-CENTERED CARE AND COORDINATED RESEARCH (2019) (1)
- Prospective Phase II Randomized Trial Comparing Proton Therapy vs. IMRT for Newly Diagnosed GBM: Secondary Analysis Comparison of Progression Free Survival between Clinical Radiological Assessment vs. Response Assessment in Neuro-Oncology (RANO) (2019) (1)
- A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. (2022) (1)
- Brain Tumor Immunology and Immunotherapy (2011) (1)
- Abstract 4291: An optimized therapeutic nanoparticle delivery platform of miRNA in preclinical murine models of malignancy (2015) (1)
- CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES (2012) (1)
- A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function. (2020) (1)
- EP-1239: Ph II randomized trial comparing cognitive outcomes of proton vs. photon radiation for glioblastoma (2018) (1)
- COMP-07. COMPARATIVE MOLECULAR LIFE HISTORY OF SPONTANEOUS CANINE AND HUMAN GLIOMA (2018) (1)
- Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM). (2018) (1)
- TMIC-13. ELUCIDATION OF MicroRNA-OSTEOPONTIN CIRCUIT IN GLIOBLASTOMA ASSOCIATED INFILTRATING MACROPHAGES (2017) (1)
- Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (2022) (1)
- Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients? (2020) (1)
- Abstract 2949: TGF-β is a key mediator of NK cell dysfunction in gliolastoma (2017) (1)
- SCIDOT-23. LOW INTENSITY PULSED ULTRASOUND ENHANCES BLOOD-BRAIN BARRIER OPENING AND IMPROVES RESPONSE TO IMMUNOTHERAPY FOR GLIOBLASTOMA (2019) (1)
- Machine learning algorithm analysis using a commercial 592-gene NGS panel to accurately predict tumor lineage for carcinoma of unknown primary (CUP). (2019) (1)
- Immunotherapeutic options for pediatric malignancies (2017) (1)
- ACTR-72. A PROSPECTIVE PHASE II RANDOMIZED TRIAL TO COMPARE INTENSITY MODULATED PROTON RADIOTHERAPY (IMPT) VS. INTENSITY MODULATED RADIOTHERAPY (IMRT) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) (2017) (1)
- FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells (2023) (1)
- FGL2 promotes tumor progression via inducing TIGIT expression on T cells in tumor microenvironment of glioma (2016) (1)
- Abstract 5088: Glioblastoma stem cell-secreted exosomes can induce a tumor supportive M2 response (2015) (1)
- Mutations of H3.3 and H3.1 in a large cohort of glioma tumors. (2019) (1)
- Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab. (2020) (1)
- Tumor-derived mesenchymal stem cells in human gliomas: Isolation and biological effects (2008) (1)
- Abstract 5606: Fibrinogen-like protein 2 drives malignant tumor progression in glioma (2017) (1)
- Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors. (2022) (1)
- Docetaxel Targets Aggressive Methylation Profiles and Serves as a Radiosensitizer in High-Risk Meningiomas. (2022) (1)
- RTHP-35. LOCAL RECURRENCE PATTERN OF PATIENTS ENROLLED ON A RANDOMIZED STUDY OF POST-OPERATIVE STEREOTACTIC RADIOSURGERY VS OBSERVATION FOR COMPLETELY RESECTED BRAIN METASTASIS (2017) (1)
- TMIC-22. DECIPHERING GLIOMA INTRINSIC TRANSCRIPTIONAL SUBTYPES IDENTIFIES TUMOR EVOLUTION ASSOCIATES WITH CHANGES IN IMMUNE-MICROENVIRONMENT (2017) (0)
- PATH-55. MUTATIONS OF H3.3 AND H3.1 IN A LARGE COHORT OF GLIOMAS (2019) (0)
- IMMU-06. REDUCTION OF CD4+ T CELLS NEGATIVELY AFFECTS SURVIVAL IN OLD BUT NOT YOUNG MICE WITH GLIOBLASTOMA (2022) (0)
- IMST-41. PARALLEL PROFILING OF MUTATIONAL LANDSCAPE, GENE EXPRESSION, AND T-CELL RECEPTOR REPERTOIRES IN SUBEPENDYMOMA REVEALS IMMUNOPHENOTYPIC HETEROGENEITY (2016) (0)
- LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease (2021) (0)
- Abstract 1489: Deposition of genetically engineered T cell attracting antigen presenting cells in the glioma microenvironment with low intensity pulsed ultrasound-based blood-brain barrier opening triggers therapeutic responses in preclinical glioma models (2021) (0)
- RTID-07. HUMAN PLACENTAL HEMATOPOIETIC STEM CELL DERIVED NATURAL KILLER CELLS (CYNK-001) FOR TREATMENT OF RECURRENT GLIOBLASTOMA (2020) (0)
- Abstract 669: Immunophenotyping of human brain tumors reveals myeloid cell mediated anti-glioma axis (2023) (0)
- IMMU-10. ESTABLISHING EFFECTIVE MODELS FOR IMMUNOTHERAPY IN GBM (2019) (0)
- IMMU-43. IMMUNE CONTEXTURE OF ISOCITRATE DEHYDROGENASE STRATIFIED HUMAN GLIOMAS REVEALED BY SINGLE-CELL TRANSCRIPTOMICS AND ACCESSIBLE CHROMATIN (2021) (0)
- A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin (2023) (0)
- Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era (2022) (0)
- Abstract 5322: Glioma cancer stem cells induce immune suppressive macrophages (2010) (0)
- FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (0)
- Clinical Management of Supratentorial Non-Skull Base Meningiomas (2022) (0)
- IMMU-36. IMMUNE RESPONSES IN CANINE GLIOMAS ARE ENRICHED AT THE INFILTRATING EDGE OF ASTROCYTOMAS (2018) (0)
- Knockout immune regulator FGL2 in tumor cells impairs tumor progression in the CNS by facilitating CD103+ dendritic cell differentiation (2019) (0)
- Immunotherapy of Central Nervous System Tumors (2005) (0)
- Abstract 1553: Intratumoral delivery of STING agonist results in radiographic response in spontaneous canine high-grade glioma (2021) (0)
- TMIC-26. MiR-181a CONTROLS THE OSTEOPONTIN-MEDIATED IMMUNE CIRCUIT IN GLIOBLASTOMA (2018) (0)
- Tumor Models (In Vivo/In Vitro) (2010) (0)
- BMET-14STAT3 INHIBITION ENHANCES THERAPEUTIC EFFICACY OF RADIATION TREATMENT AGAINST ESTABLISHED BRAIN METASTASIS IN MURINE MELANOMA MODEL (2015) (0)
- Aspirin and immunotherapy: a Faustian bargain? (2023) (0)
- RARE-05. TUMOR PROFILING REVEALS EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) AND ENHANCED IMMUNE SUPPRESSION IN GLIOSARCOMAS RELATIVE TO GLIOBLASTOMA (2018) (0)
- TMIC-78. CIRCADIAN REGULATOR CLOCK DRIVES IMMUNOSUPPRESSION IN GLIOBLASTOMA (2022) (0)
- Functional imaging of immune cell subpopulations in the tumor microenvironment: clinical implications (2022) (0)
- A phase I/II clinical trial of autologous CMV-specific cytotoxic T cells (CMV-TC) for glioblastoma: Dose escalation results. (2018) (0)
- Characterization of microglia phenotype and function within malignant human gliomas: A potential mechanism for immune anergy (2005) (0)
- IMPS-22FGL2 AS A MULTI-MODALITY REGULATOR OF TUMOR-MEDIATED IMMUNE SUPPRESSION (2015) (0)
- ANovel Inhibitor of SignalTransducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous SystemMelanoma and Inhibits Regulatory TCells (2008) (0)
- Small molecule inhibition of stat3 enhances survival in mice with intracerebral melanoma (2008) (0)
- IMPS-41IMMUNE MODULATORY NANOPARTICLE THERAPEUTICS (2015) (0)
- phos-Mechanisms of action of rapamycin in gliomas 1 (2004) (0)
- The kynurenine pathway implicated in patient delirium: possible indications for indoleamine 2,3 dioxygenase inhibitors (2023) (0)
- Preferential Migration of T Regulatory Cells Mediated by Glioma-Secreted Chemokines (49.3) (2007) (0)
- SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression (2022) (0)
- 892 Validation of Docetaxel as a Radiosensitizer in High-Risk Meningiomas Based on DNA Methylation Profiling (2023) (0)
- Modulation of antiangiogenic resistance: Targeting the JAK/STAT3 pathway in glioblastoma. (2012) (0)
- Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease. (2023) (0)
- We gratefully appreciate Chamberlain's 1 kind and thoughtful (2011) (0)
- Concomitant chemotherapy and immunotherapy (2006) (0)
- GENE-57. COMPARATIVE MOLECULAR LIFE HISTORY OF SPONTANEOUS CANINE AND HUMAN GLIOMA (2019) (0)
- American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. (2021) (0)
- Organ specificity of cancer metastasis depends on the adaptive immune surveillance and the neuronal chemokine fractalkine (TUM10P.1030) (2015) (0)
- GENE-41. UNDERSTANDING THE DIFFERENCES IN ADOLESCENT AND YOUNG ADULT (AYA) GLIOMAS AND OLDER ADULT (OA) GLIOMAS BASED ON FUNCTIONAL MOLECULAR SUBGROUPS (2019) (0)
- IMMU-42. CD8+ T-CELLS MEDIATE IMMUNOEDITING, AND INFLUENCE GENOTYPE, TUMOR ONCOGENIC PATHWAYS AND MICROENVIRONMENT DURING PROGRESSION OF MURINE GLIOMAS (2019) (0)
- Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade (2023) (0)
- Abstract B62: miR-124 systemically enhances antitumor clearance by inhibiting STAT3 signaling and reversing glioma-associated immune suppression. (2013) (0)
- Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment (2023) (0)
- IMPS-34INNATE IMMUNOLOGICAL COMPENSATORY CONTROL OF GLIOMAGENESIS AND MALIGNANT TRANSFORMATION IN MURINE CD8α KNOCKOUT MODELS (2015) (0)
- IMPS-04TUNING SENSITIVITY OF CHIMERIC ANTIGEN RECEPTOR TO EGFR DENSITY LIMITS RECOGNITION OF NORMAL TISSUE WHILE MAINTAINING POTENT ANTI-TUMOR ACTIVITY (2015) (0)
- MPTH-45. MEDULLOBLASTOMA: CANDIDATE PATHWAYS FOR NOVEL TREATMENT STRATEGIES (2016) (0)
- Abstract 5746: CRISPR9-mediated FGL2-KO in tumor cells impairs tumor progression in brain and triggers antitumor immune memory systematically via NF-κB dependent Batf3 expression in DCs (2018) (0)
- Abstract LB335: Establishment of the effective dose of the STAT3 inhibitor WP1066 used in combination with STING activation for reprograming the preclinical glioma microenvironment (2023) (0)
- IMST-49. MECHANISM AND THERAPEUTIC TARGETING OF OSTEOPONTIN-MEDIATED IMMUNE SUPPRESSION IN GBM (2016) (0)
- IT-22TARGETING THE IMMUNE CHECKPOINT NETWORK WITH miR-138 EXERTS THERAPEUTIC EFFICACY IN MURINE MODELS OF GLIOMA (2014) (0)
- Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas (2023) (0)
- RARE-22. FREQUENT HIGH TUMOR MUTATIONAL BURDEN (TMB) AND PD-L1 EXPRESSION IN PRIMARY CNS LYMPHOMA (PCNSL) (2018) (0)
- QOL-06. PREDICTING VENOUS THROMBOEMBOLISM IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMAS (2022) (0)
- Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors 1 (2003) (0)
- Abstract 2548: The central nervous system immune cell interactome is a function of cancer lineage, tumor microenvironment and STAT3 expression (2022) (0)
- Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes (2018) (0)
- 1001 Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas (2022) (0)
- Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC). (2021) (0)
- cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma (2022) (0)
- ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS (2018) (0)
- NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT (2019) (0)
- Abstract 2259: Evaluation of polymorphisms in myeloid-associated genes and glioma survival (2017) (0)
- Reply to J.W. Locasale et al (2012) (0)
- OTME-23. Single-cell transcriptomic and epigenomic immune landscape of isocitrate dehydrogenase stratified human gliomas (2021) (0)
- Abstract LB-123: Analyses of anti-cancer testis antigen antibodies in glioma patients treated with Delta-24 oncolytic adenovirus (2012) (0)
- MNGO-10. PD-1/PD-L1 AND GENOMIC EXPRESSION PROFILING OF MENINGIOMAS (2016) (0)
- TMIC-33. THE ROLE OF FIBRINOGEN-LIKE PROTEIN 2 ON IMMUNOSUPPRESSION AND MALIGNANT PROGRESSION IN GLIOMA (2018) (0)
- Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. (2023) (0)
- Cancer Therapy : Preclinical Clinical Cancer Research Inhibition of p-STAT 3 Enhances IFN-α Efficacy against Metastatic Melanoma in a Murine Model (2010) (0)
- PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2010) (0)
- Immune checkpoint blockade in glioma (2019) (0)
- Abstract SP084: Replication stress response defects predict responses to ICT in non-hypermutated tumors (2021) (0)
- Correction to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling (2021) (0)
- Test sanguin de détection du cancer (2010) (0)
- Abstract 3783: Pharmacokinetics and CNS biodistribution of WP1066, a novel small molecule inhibitor of STAT-3 phosphorylation (2012) (0)
- Next-Generation Sequencing of a Glioblastoma with True Epithelial Differentiation. (2021) (0)
- TMIC-10PLEIOTROPY OF TUMOR-ASSOCIATED MYELOID CELLS WITHIN HUMAN GLIOBLASTOMA (2015) (0)
- Immune landscape of a genetically-engineered murine model of glioma relative to human glioma by single-cell sequencing (2020) (0)
- P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress (2018) (0)
- Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts (2022) (0)
- IB-08COMPUTATIONAL IMAGING FEATURES DERIVED FROM MRI IMAGES OF THE BRAIN CAN DISCRIMINATE IMMUNE SIGNATURE STATUS IN GLIOBLASTOMA MULTIFORME (GBM). (2014) (0)
- Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (0)
- RARE-38. NOVEL TARGETS IN EPENDYMAL TUMORS (2016) (0)
- Comparison of molecular alteration in glioblastoma tumors from old and young patients. (2016) (0)
- CTIM-24. NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA (2022) (0)
- Postoperative risk of IDH mutant glioma-associated seizures and their potential management with IDH mutant inhibitors. (2023) (0)
- IMMU-48. GLIOMA IMMUNE PROFILING REVEALS UNIQUE IMMUNE THERAPEUTIC OPPORTUNITIES (2018) (0)
- Abstract P2-09-09: Polyligand profiling differentiates cancer patients according to their benefit of treatment (2018) (0)
- IMPS-29REFUTING BRAIN IMMUNE PRIVILEGE: LONGITUDINAL MULTIPHOTON IMAGING THROUGH SKULL WINDOWS REVEALS THE IMMUNE SURVEILLANCE OF BRAIN METASTASES AND ITS REGULATION BY FRACTALKINE (2015) (0)
- MLTI-01. IMMUNOLOGICAL REPROGRAMMING IN THE CNS TUMOR MICROENVIRONMENT AND THERAPEUTIC EFFICACY OF RADIOTHERAPY WITH STAT3 BLOCKADE (2019) (0)
- Serum microRNA profiling in patients with glioblastoma: a survival analysis (2017) (0)
- Synergistic effect of immunotherapy and chemotherapy in cancers: Perspective in high grade glioma treatment (2006) (0)
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma (2019) (0)
- RTHP-18. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR NEWLY DIAGNOSED GBM: SECONDARY ANALYSIS COMPARISON OF GENDER AND NEUTROPHIL-LYMPHOCYTE RATIO (NLR) IN GBM OUTCOMES (2019) (0)
- Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. (2023) (0)
- TMIC-04. GLIOBLASTOMA-ASSOCIATED MYELOID CELLS DISPLAY NONPOLARIZED M0 MACROPHAGE PHENOTYPE (2016) (0)
- Key Word and Full-Text Search Emerging Immune Therapeutics Targeting Glioblastoma-Mediated Immune Suppression : Dark Before the (2016) (0)
- P01.058 Higher immune associated markers (PD-L1, PD-1, TMB, MSI) in gliosarcoma compared to glioblastoma. (2018) (0)
- IMMU-17. REDUCING THE EX VIVO MANUFACTURING TIME OF EGFRVIII-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IMPROVES PHENOTYPE AND DEMONSTRATES POTENT ANTI-GLIOMA FUNCTION IN VIVO (2017) (0)
- Immune landscape of isocitrate dehydrogenase stratified human 1 gliomas 2 (2022) (0)
This paper list is powered by the following services:
Other Resources About Amy B. Heimberger
What Schools Are Affiliated With Amy B. Heimberger?
Amy B. Heimberger is affiliated with the following schools:
